Anti-inflammatory Therapy Progress in Major Adverse Cardiac Events after PCI: Chinese and Western Medicine.
10.1007/s11655-023-3638-8
- Author:
Xue-Yu REN
1
;
Ying-Fei LI
1
;
Hui-Qing LIU
1
;
Hui LIN
1
;
Qian LIN
2
;
Yang WU
3
;
Jie WAN
3
;
Jin-Jin LU
3
;
Jing LIU
3
;
Xiao-Yun CUI
4
Author Information
1. Graduate School of Beijing University of Chinese Medicine, Beijing, 100029, China.
2. Department of Cardiology, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, 100700, China.
3. Department of Cardiology, Dong Fang Hospital, Beijing University of Chinese Medicine, Beijing, 100078, China.
4. Department of Cardiology, Dong Fang Hospital, Beijing University of Chinese Medicine, Beijing, 100078, China. yun6171@126.com.
- Publication Type:Review
- Keywords:
Chinese medicine;
anti-inflammatory therapy;
inflammatory response;
major adverse cardiac events;
percutaneous coronary intervention
- MeSH:
Humans;
Percutaneous Coronary Intervention/methods*;
Acute Coronary Syndrome/drug therapy*;
Coronary Disease;
Treatment Outcome;
Stents/adverse effects*
- From:
Chinese journal of integrative medicine
2023;29(7):655-664
- CountryChina
- Language:English
-
Abstract:
Acute coronary syndrome (ACS) is one of the leading causes of death in cardiovascular disease. Percutaneous coronary intervention (PCI) is an important method for the treatment of coronary heart disease (CHD), and it has greatly reduced the mortality of ACS patients since its application. However, a series of new problems may occur after PCI, such as in-stent restenosis, no-reflow phenomenon, in-stent neoatherosclerosis, late stent thrombosis, myocardial ischemia-reperfusion injury, and malignant ventricular arrhythmias, which result in the occurrence of major adverse cardiac events (MACE) that seriously reduce the postoperative benefit for patients. The inflammatory response is a key mechanism of MACE after PCI. Therefore, examining effective anti-inflammatory therapies after PCI in patients with ACS is a current research focus to reduce the incidence of MACE. The pharmacological mechanism and clinical efficacy of routine Western medicine treatment for the anti-inflammatory treatment of CHD have been verified. Many Chinese medicine (CM) preparations have been widely used in the treatment of CHD. Basic and clinical studies showed that effectiveness of the combination of CM and Western medicine treatments in reducing incidence of MACE after PCI was better than Western medicine treatment alone. The current paper reviewed the potential mechanism of the inflammatory response and occurrence of MACE after PCI in patients with ACS and the research progress of combined Chinese and Western medicine treatments in reducing incidence of MACE. The results provide a theoretical basis for further research and clinical treatment.
